Cargando…
Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma
Sarcomas are rare tumors with generally poor prognosis, for which current therapies have shown limited efficacy. Histone deacetylase inhibitors (HDACi) are emerging anti-tumor agents; however, little is known about their effect in sarcomas. By using established and patient-derived sarcoma cells with...
Autores principales: | Di Martile, Marta, Desideri, Marianna, Tupone, Maria Grazia, Buglioni, Simonetta, Antoniani, Barbara, Mastroiorio, Carlotta, Falcioni, Rita, Ferraresi, Virginia, Baldini, Nicola, Biagini, Roberto, Milella, Michele, Trisciuoglio, Daniela, Del Bufalo, Donatella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833676/ https://www.ncbi.nlm.nih.gov/pubmed/29472530 http://dx.doi.org/10.1038/s41389-018-0026-x |
Ejemplares similares
-
BCL-X(L) overexpression promotes tumor progression-associated properties
por: Trisciuoglio, Daniela, et al.
Publicado: (2017) -
Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation
por: Angiolilli, Chiara, et al.
Publicado: (2018) -
The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis
por: Celesia, Adriana, et al.
Publicado: (2022) -
Long non-coding RNA H19 enhances the pro-apoptotic activity of ITF2357 (a histone deacetylase inhibitor) in colorectal cancer cells
por: Zichittella, Chiara, et al.
Publicado: (2023) -
Analysis of Givinostat/ITF2357 Treatment in a Rat Model of Neonatal Hypoxic-Ischemic Brain Damage
por: Pawelec, Paulina, et al.
Publicado: (2022)